Abstract
Serotonin-reuptake inhibitors (SRIs, SSRIs) and cognitive behavioral therapy (CBT) are currently considered the first-line treatments for body dysmorphic disorder (BDD). A practice guideline and a Cochrane review that recommend these treatments have been published,1,2 even though treatment research on BDD is still quite limited. The publication of these landmark documents underscores how important it is for clinicians to be knowledgeable about current treatment recommendations for BDD, which is a relatively common and often disabling disorder that is associated with high morbidity and mortality (see Didie et al, this issue).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
